创新药临床试验五维量化风险评估模型的构建与研究OA
Development and Study of a Five-Dimensional Quantitative Risk Assessment Model for Clinical Trials of Innovative Drugs
目的:针对我国创新药临床试验数量快速增长但监管效能有限的现状,构建并评价兼具国际视野与中国特色的基于风险的监管理论框架与实用工具体系.方法:采用比较研究、改良德尔菲法和层次分析法,开发创新药临床试验五维量化风险评估工具,并对53项临床试验进行回顾性实证研究,采用描述性统计分析风险指数(RI)的分布,结合 K-means 聚类分析确定风险分级界值,并对风险等级与实际检查类型进行交叉分析.结果:形成包含5个一级维度、15个二级指标的风险评估工具,涵盖药物创新性、试验复杂性、研究者/机构能力、试验参与者风险及申办者成熟度.53项临床试验按高风险(RI≥60分)、中风险(40分≤RI<60分)和低风险(RI<40分)分级,分别为14项、31项和8项.各风险等级的总体检查覆盖率接近,检查类型与风险等级的总体关联未达到统计学显著性.结论:基于风险的监管理念已成为国际共识,其在我国的有效落地需依赖本土化、可量化的技术工具.本研究开发的五维量化风险评估工具可为临床试验风险分级、检查项目选择及监管强度调整提供量化参考及可复现的决策支持,有望为推动我国临床试验科学监管、资源配置优化及国际监管协同提供支持.该工具信度、效度及改善监管资源配置的实际效果,仍需通过多中心、大样本的前瞻性研究进一步验证.
Objective:This study aims to develop and evaluate a risk-based regulatory framework and practical assessment tools informed by international experience and adapted to the Chinese context,in response to the rapid growth in clinical trials of innovative drugs and constraints on regulatory effectiveness in China.Methods:A five-dimensional quantitative risk assessment tool for clinical trials of innovative drugs was developed using comparative research,a modified Delphi method,and the analytic hierarchy process.A retrospective empirical study was conducted involving 53 clinical trials.Descriptive statistics were used to characterize the distribution of the risk index(RI),and K-means clustering informed the determination of risk classification thresholds.Cross-tabulation analysis was performed to examine the association between risk categories and the types of regulatory inspection received.Results:The tool comprised 5 primary dimensions and 15 secondary indicators,covering drug innovativeness,trial complexity,investigator/site capability,risks to trial participants,and sponsor maturity.Of the 53 trials,14 were classified as high risk(RI≥60),31 as moderate risk(40≤RI<60),and 8 as low risk(RI<40).Overall inspection coverage was similar across risk categories,and the overall association between inspection type and risk category was not statistically significant.Conclusion:Risk-based regulation is widely recognized internationally,and its effective implementation in China requires locally adapted,quantifiable technical tools.The proposed five-dimensional risk assessment tool may provide a quantitative basis and reproducible decision support for classifying clinical trial risks,selecting trials for inspection,and adjusting regulatory intensity.It has the potential to support scientifically informed clinical trial oversight,optimize resource allocation,and facilitate international regulatory collaboration.Its reliability,validity,and actual impact on regulatory resource allocation require further evaluation through large,multicenter prospective studies.
孙搏;孔丽亚;李香玉
上海药品审评核查中心甘肃省药品监督管理局审核查验中心(甘肃省疫苗检查中心)上海药品审评核查中心
医药卫生
创新药临床试验基于风险的监管量化评估工具监管科学
innovative drugsclinical trialsrisk-based regulationquantitative assessment toolsregulatory science
《中国食品药品监管》 2026 (9)
92-103,12
2025年中国药品监督管理研究会课题(2025-Y-Y-017)上海市市场监督管理局政策研究课题(20250269)
评论